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Abstract
Background: Following recent approval of pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF),
questions arise about the use of these antifibrotics in patients awaiting lung transplantation (LTx).
Methods: Safety and efficacy of antifibrotic drugs in IPF patients undergoing LTx were investigated in a single-centre
retrospective cohort analysis.
Results: A total of nine patients, receiving antifibrotic therapy for 419 ± 315 days until subsequent LTx, were included. No
major side effects were noted. Significant weight loss occurred during antifibrotic treatment (p = 0.0062). FVC tended to
stabilize after 12 weeks of treatment in most patients. A moderate decline in FVC, TLC and DLCO was noted during the
whole pretransplant time period of antifibrotic therapy. Functional exercise capacity and lung allocation score remained
unchanged. No post-operative thoracic wound healing problems, nor severe early anastomotic airway complications
were attributable to prior antifibrotic treatment. None of the patients developed chronic lung allograft dysfunction after a
median follow-up of 19.8 (11.2–26.5) months; and post-transplant survival was 100% after 1 year and 80% after 2 years.
Conclusions: Antifibrotic drugs can probably be safely administered in IPF patients, possibly attenuating disease
progression over time, while awaiting LTx.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive and
lethal disease characterized by chronic, fibrosing intersti-
tial pneumonitis of unknown cause, associated with a
histopathologic and/or radiologic pattern of usual intersti-
tial pneumonia (UIP) [1]. The course of the disease is
unpredictable. Most patients demonstrate a slow, gradual
progression; some patients remain stable; while others
have an accelerated decline, sometimes due to repeated
exacerbations. Consequently, respiratory failure is the
most common cause of death in IPF. Once diagnosed,
timely referral to an expert centre is therefore essential to
assess eligibility for pharmacological therapy and/or lung
transplantation (LTx) [2].
In October 2014, the US Food and Drug Administration
(FDA) approved two anti-fibrotic drugs for IPF - pirfeni-
done and nintedanib - based on the results of large
randomized clinical trials (CAPACITY-1, CAPACITY-2
and ASCEND with pirfenidone; TOMORROW,
INPULSIS-1 and INPULSIS-2 with nintedanib) demon-
strating a reduction in the rate of decline in forced vital
capacity (FVC) in mild to moderate IPF [3–5]. Post-hoc
analysis also demonstrated a risk reduction for IPF-
related mortality with pirfenidone compared to placebo
(HR 0.32, 95% CI 0.14–0.76, p = 0.006) [6], a same
trend which was also observed with nintedanib (HR
0.70; 95% CI 0.46–1.08; p = 0.0954) [7].
Despite these positive findings, it should be emphasized
that both antifibrotic drugs do not represent a ‘cure’ for
IPF, but only aim to attenuate the decline in FVC, at best
resulting in temporary disease stabilization. Moreover, side
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effects (typically nausea, anorexia, malaise, or rash for pir-
fenidone; and diarrhea for nintedanib) or adverse events
(mainly toxic hepatitis) may force some patients to reduce
or even stop treatment, which may again accelerate dis-
ease progression. Hence, early evaluation and referral for
LTx, which presently remains the only definitive treatment
option for well-selected IPF patients, is highly recom-
mendable, particularly since IPF patients have the highest
waiting list mortality, due to disease progression. The
recent introduction of the lung allocation score (LAS) in
some countries may nevertheless decrease future waiting
list mortality in IPF. Implementation of the LAS indeed
has already led to a substantial increase in the proportion
of LTx performed for IPF, making it the most common
indication for LTx and reducing waiting list time for IPF
in these countries [8].
With increasing use of antifibrotics following recent
FDA approval, questions arise about their safety in IPF
patients undergoing LTx, yet safety data in this specific
setting are currently lacking. The antifibrotic properties
of pirfenidone result from inhibition of transforming
growth factor (TGF)-β expression, thus attenuating
myofibroblast differentiation and fibroblast activity [9].
Nintedanib is a tyrosine kinase inhibitor, which blocks
receptors for platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), and vascular endothelial
growth factor (VEGF), thus inhibiting downstream
signaling in (myo-)fibroblasts [10]. Both antifibrotics
may hence theoretically impair post-operative wound
healing and/or cause bronchial anastomotic complica-
tions following LTx. Nintedanib, by inhibition of VEGF
and PDGF, may in theory also result in an increased
peri-operative bleeding risk. Moreover, it is unclear
whether antifibrotic treatment, when effectively achiev-
ing disease stabilization for several months, would influ-
ence LAS or may even interfere with referral for LTx,
given an upper age limit for LTx used in most centres.
In the current study we therefore report on safety
and efficacy of pretransplant antifibrotics in IPF pa-
tients undergoing LTx. Pretransplant pulmonary func-
tion, functional exercise capacity; and immediate and
long-term post-operative outcomes, including the early
post-operative course, presence of bronchial anasto-
motic complications, chronic lung allograft dysfunction
(CLAD) and survival, were retrospectively assessed.
Methods
Study design and population
This is a single-centre, retrospective analysis of IPF patients
undergoing LTx in a large volume transplant centre at a ter-
tiary care hospital. The current study was approved by the
Leuven University Hospital Ethical Review Board (S51577)
and patients gave informed consent. IPF diagnosis was con-
firmed in by a multidisciplinary board discussion, including
an expert chest physician specialized in interstitial lung dis-
ease (ILD) (WW), an experienced chest imaging radiologist
and a specialized lung-pathologist (EKV). For the current
study, we included all IPF patients up to December 2015
who had undergone LTx in our centre whilst being treated
with either pirfenidone or nintedanib. There were no IPF
patients receiving antifibrotic drugs who died on the wait-
ing list before LTx.
Pirfenidone was initiated between September 2008 and
September 2013; and patients were subsequently trans-
planted between November 2008 and April 2015. Ninte-
danib was started between August 2010 and January
2012; and patients were transplanted between March
2011 and October 2014. In Belgium, pirfenidone was ap-
proved for mild to moderate IPF (FVC >50%predicted
(%pred) and Diffusion Capacity (DLCO) >35%pred) in
December 2012 and nintedanib has been approved for
mild to severe IPF (FVC ≥50%pred and DLCO ≥30%pred)
since December 2015. Patients in whom antifibrotic
therapy was initiated before these respective dates thus
received the drugs in the context of clinical trials, there-
after patients received open-label treatment according to
reimbursement rules. All IPF patients were evaluated on
regular intervals (every 3 to 4 months) at a specialized
outpatient ILD consultation by a specialized physician
(WW) and nurse, who checked compliance and toler-
ance of their antifibrotic therapy.
Data collection
Data were retrospectively collected from the patients’ elec-
tronical medical files, including clinical and demographi-
cal variables, duration of antifibrotic treatment, laboratory
results, anastomotic problems (scored according to MDS
classification as previously reported, [11]), evolution of
pulmonary function and functional exercise capacity. The
estimated annual decline in pulmonary function parame-
ters (FVC, Total Lung Capacity (TLC) and DLCO) was cal-
culated based on the difference in pulmonary function
parameters between the start of antifibrotic therapy (‘base-
line’) and at the time of LTx, adjusted for the number of
months therapy was taken (monthly decline) and extrapo-
lated to 1 year (monthly decline x12). The same approach
was used regarding the decrease in six minute walking test
(6MWT) between start of therapy and LTx. LAS was
retrospectively assessed at start of antifibrotic therapy, at
LTx listing (data summarized in Table 1) and at LTx. How-
ever, we used LAS at start of antifibrotic therapy for
further statistical analyses regarding pre-LTx evolution of
LAS, because most patients were initiated on antifibrotics
before LTx listing.
Historical controls
We additionally identified a comparable group of histor-
ical controls (n = 6), which consisted of IPF patients who
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Table 1 Recipient and donor demographics of the IPF treatment group and historical control group
ID Recipient
Gender
(M/F)
Recipient
Age (Years)
Anti-fibrotic
Drug
Cardio-
Pulmonary
Rehabilitation
Time on
Therapy
(Days)
FVC at
start
(%pred)
TLC at start
(%pred)
DLCO at start
(%pred)
6MWT
at start
(m)
Time on WL
(Days)
LAS at
listing
Type of
LTx (S/SS)
Donor
Gender
(M/F)
Donor
Age
(Years)
Type of
Donor
CMV
Donor/
Recipient
1 F 62 PFD no 735 91 72 46 529 762 32 SS F 17 DBD D+/R+
2 M 61 PFD CPR 545 71 61 37 379 179 31 SS F 67 DCD
cat III
D-/R-
3 M 51 PFD CPR 387 88 80 47 552 29 35 SS M 37 DBD D+/R-
4 M 63 PFD CPR 539 52 45 32 384 51 30 SS M 55 DBD D-/R+
5 M 55 PFD CPR 188 56 52 35 631 25 29 SS M 23 DBD D+/R-
6 M 64 PFD no 115 62 48 39 503 163 33 SS M 35 DCD
cat V
D+/R+
7 M 64 PFD no 65 79 56 28 267 419 37 S F 42 DBD D+/R-
8 M 65 NIN no 1003 80 69 58 598 155 31 SS M 62 DBD D+/R-
9 M 56 NIN no 194 58 56 29 275 74 32 SS M 39 DCD
cat III
D-/R-
Mean or
Median
60.1 ± 4.9 419 ± 315 70.8 ±
14.5
59.9 ± 11.7 39.0 ± 9.8 457.6 ± 135.6 155
(40–299)
32.2 ± 2.5 43.6
± 17.1
1 M 57 / no / / / / / 279 33 SS F 48 DCD
cat III
D-/R+
2 M 62 / no / / / / / 153 35 SS F 66 DBD D+/R+
3 M 55 / no / / / / / 17 34 SS M 74 DBD D+/R+
4 M 59 / CPR / / / / / 274 32 SS M 22 DCD
cat III
D-/R+
5 M 59 / CPR / / / / / 253 29 SS M 57 DBD D-/R-
6 M 65 / CPR / / / / / 112 26 S M 37 DBD D+/R+
Mean or
Median
59.5 ± 3.6a 203
(88–275)a
31.5 ± 3.4a 50.7 ±
19.a
ID Ischemic
Time 1th
/2nd Lung
(min)
Immuno-
suppressive
Regimen
Time to
Extubation
(Hours)
PGD
at 72 h
Time on
ICU (Days)
Time in
Hospital
(Days)
AR or LB
Episodes
(Number)
Most
Severe
AR or LB
(Grade)
Respiratory
infection
before
Discharge
(Presence = 1)
Respiratory
Pathogen
before
Discharge
Anastomotic
Complications
(Details in Text)
1 187/320 rATG/FK/
MMF/CS
34 0 6 16 0 0 0 / 0
2 432/580 rATG/FK/
MMF/CS
20 3 7 20 1 1 1 E. coli, S.
viridans
M2aD0aS0
(POD 30)
3 498/694 No ATG,
FK/MMF/CS
37 0 4 16 2 2 1 A. baumanii,
E. coli, S.
aureus
M3bD2cS2f
(POD 204)
4 417/631 65 1 13 26 1 1 0 /
D
elanote
et
al.BM
C
Pulm
onary
M
edicine
 (2016) 16:156 
Page
3
of
10
Table 1 Recipient and donor demographics of the IPF treatment group and historical control group (Continued)
rATG/FK/
MMF/CS
M2aD0aS0
(POD 30)
5 366/515 rATG/FK/
MMF/CS
41 2 6 17 0 0 1 C. freundii 0
6 385/582 rATG/FK/
MMF/CS
37 1 4 16 3 2 0 / 0
7 341 rATG/CsA/
AZA/CS
33 2 3 21 0 0 1 H. influenza,
MRSA
0
8 180/356 rATG/FK/
MMF/CS
178 3 10 28 1 3 1 H. influenza,
S.
pneumoniae
M1aD0aS0 (POD 90)
9 239/356 rATG/FK/
MMF/CS
38 2 5 23 1 2 0 / 0
338 ±
113/504 ±
142
37 (33.5–53) 2 (0.5–2.5) 6.4 ± 3.2 20.3 ±
4.6
1 (0–1.5) 1 (0–2)
1 404/626 rATG/FK/
MMF/CS
72 0 7 19 1 2 0 / 0
2 220/412 rATG/FK/
MMF/CS
16 1 7 25 2 3 1 S. aureus M3bD0aS0 (POD 30)
3 288/431 rATG/FK/
MMF/CS
432 3 60 253 1 1 1 P. aeruginosa,
K. pneumoniae,
M3bD2bS0 (POD 40)
4 276/423 rATG/FK/
MMF/CS
48 2 15 32 1 1 1 E. faecalis M2aD0aS0 (POD 14)
5 209/439 rATG/CsA/
AZA/CS
48 2 23 32 0 0 1 K. oxytoca M3aD0S0 (POD 17)
6 186 rATG/CsA/
AZA/CS
24 1 8 20 2 1 0 / 0
264 ±
79a/466
± 90a
48 (22–162)a 1.5 (0.8–2.3)a 20.0 ±
20.6b
63.5 ±
93a
1
(0.75–2.0)a
1
(0.75–2.25)a
ID Time of
Follow-up
(Months)
Status
(Dead = 1)
Last FVC
Post-LTx
(%pred)
Last FEV1
Post-LTx
(%pred)
Last FEV1
/FVC Post-LTx
(%pred)
1 7.7 0 145 147 86
2 8.6 0 106 90 66
3 16.9 0 70 68 77
4 21.9 0 90 67 58
5 25.8 0 93 93 80
6 27.1 0 123 126 79
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Table 1 Recipient and donor demographics of the IPF treatment group and historical control group (Continued)
7 19.8 1 110 107 76
8 13.8 0 119 115 75
9 56.3 0 132 141 84
19.8
(11.2–26.5)
109 ± 23.1 106 ± 29.1 75.7 ± 8.8
1 14.9 0 117 76 66
2 23.5 0 104 99 76
3 37.0 0 67 61 73
4 38.6 0 107 92 67
5 52.4 0 104 58 43
6 12.2 1 79 82 81
30.3
(14.2–42.1)
96.3 ± 19.1 78.0 ± 16.4 67.7 ± 13.3
Data are expressed as mean ± SD, median (interquartile range) or as total values where appropriate
Abbreviations: 6MWT 6 min walking test, AR Acute (cellular) Rejection, AZA azathioprine, cat category, CMV Cytomegalovirus, CPR Cardio-Pulmonary Rehabilitation, CS corticosteroids, CsA cyclosporine A, D donor, DBD
donation after brain death, DCD donation after cardiac death, DLCO diffusion capacity, F Female, FK tacrolimus, FVC Forced Vital Capacity, ICU Intensive Care Unit, ID identification, LAS lung allocation score, LB lympho-
cytic bronchiolitis, LTx lung transplantation, M male, MDS severity of anastomotic complication according to MDS classification, MMF mycophenolate mofetil, NIN nintedanib, PFD pirfenidone, PGD primary graft dysfunc-
tion, R recipient, rATG rabbit Anti-Thymocyte Globulin, S single, SS sequential single, TLC Total Lung Capacity, WL waiting list
a:p > 0.05 (not statistically significant compared to treated group), b:p = 0.021 compared to treated group
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did not receive antifibrotic therapy before LTx, but were
transplanted in the same era (7/2010 to 9/2014), had
comparable age and lung function at the time of LTx
compared to the treatment group: FVC 57.0 (43.0–69.8)
%pred (p = 0.69 vs. treatment), TLC 53.0 (42.5–71.0)
%pred (p = 1.0 vs. treatment) and DLCO 21.5 (17.0–29.2)
%pred (p = 0.11 vs. treatment). Given the small number
of available patients, it was impossible to match both
groups any further regarding concurrent emphysema
(but TLC and DLCO were comparable between both
groups, thus excluding major differences due to emphy-
sema), pulmonary hypertension (was not routinely
assessed in non-treated IPF patients, no comparison pos-
sible with treated group who were all screened at start of
antifibrotic therapy) or cardiovascular disease (but major
cardiovascular disease is generally an exclusion-criterion
to proceed to LTx in any patient). Reasons for not starting
antifibrotic therapy in these matched historical controls
were: absence of consent (n = 3), DLCO too low for study-
inclusion (n = 2) and pending approval by the health care
authorities whilst awaiting LTx (n = 1). These historical
controls were only used as comparator for the IPF
group treated with antifibrotics regarding the annual
pre-transplant decline in pulmonary function; and
some mportant early post-transplant outcome param-
eters, including rates of PGD, infection, rejection and
anastomotic complications. These historical patients
were not the main aim of this study, which focusses
on reporting safety and efficacy of antifibrotics in IPF
patients undergoing LTx.
Statistical analysis
All analyses were performed using Graphpad Prism 5a
software (San Diego, USA). Results are expressed as
mean (± standard deviation) or median (interquartile
range) where appropriate. Group means were compared
using paired or unpaired t-test; Mann-Whitney test or
Wilcoxon signed rank test for normally or not-normally
distributed variables, respectively. All reported p-values
are two-tailed and p < 0.05 was considered significant.
Results
Patients’ characteristics
A total of 9 IPF patients were treated with antifibrotics
and subsequently underwent LTx: pirfenidone n = 7 (n = 2
study vs. n = 5 open-label treatment), nintedanib n = 2
(both in study). All patients, but one, underwent bilateral
LTx and all, but one, were male. Age at LTx was 60.1 ±
4.9 years. Five patients were on continuous oxygen ther-
apy (4 (3.5–4.0) Liters/min) before LTx, while 4 were not
(Table 1). Antifibrotic therapy had been initiated 362
(152–578) days before listing for LTx in 6/9 patients,
whereas in 3/9 patients antifibrotics were started 48
(27–354) days after transplant listing. In all 9 cases
antifibrotic therapy was continued until the day of trans-
plant procedure. Total duration of antifibrotic therapy
until LTx was 419 ± 315 days, or 13.8 ± 10.3 months. All
patients received the full, recommended dose (i.e. 801 mg
tid for pirfenidone and 150 mg bid for nintedanib).
Nausea was reported as main side-effect of antifibrotic
therapy in 9/9 patients; and 7/9 patients lost weight dur-
ing treatment (n = 6 pirfenidone, n = 1 nintedanib), in
one patient (on pirfenidone) weight remained stable and
one patient (on nintedanib) gained 1 kg. Overall, body
mass index (BMI) decreased from 27.3 ± 3.2 kg/m2 to
25.8 ± 3.3 kg/m2 (p = 0.0063) during antifibrotic treat-
ment, with an absolute weight loss of 329 ± 360 g per
month of treatment (p = 0.0062). None of the patients
developed toxic hepatitis, nor discontinued their therapy
due to other severe side-effects or adverse events. No
acute IPF exacerbations occurred in any of the patients
during antifibrotic treatment.
Evolution of pretransplant pulmonary function, functional
exercise capacity, pulmonary hypertension, renal function
and LAS
Spirometry was performed at the start of antifibrotic
treatment (‘baseline’) and during subsequent follow-up.
Consecutive spirometry after six months of antifibrotic
therapy was only available in 6/9 patients, as 3 patients
(n = 2 pirfenidone, n = 1 nintedanib) underwent LTx
within 6 months after initiating therapy (Fig. 1). In these
6/9 patients (n = 5 pirfenidone, n = 1 nintedanib), the
absolute decline in FVC after 12 weeks of treatment
compared to baseline was −7.0%pred (−1.8 to −11.5),
with 4/6 (66.6%) patients having <10% decline in FVC
%pred; and only 2/6 (33.3%) patients demonstrating a
≥10% decline in FVC %pred (p = 0.063 vs. start). Never-
theless, an overall absolute decrease in FVC, TLC and
DLCO during the whole pretransplant antifibrotic treat-
ment period (i.e. 419 ± 315 days or 59 ± 44 weeks) was
observed in these 6/9 patients (Fig. 2).
The calculated annual decline during treatment for
all included patients was: FVC 322.0 (148.3–1074.0)
mL or 6.6 (0–23.8) %pred, TLC 360.0 (157.5–1818.0)
mL or 6.0 (2.0–25.7) %pred; and DLCO 0.77 (0.40–1.96)
mmol/min/Kpa or 7.5 (4.7–18.6) %pred. Interestingly,
the measured annual rate of decline in the matched his-
torical controls (without antifibrotic therapy) during
the year preceding LTx appeared to be somewhat more
severe compared to the group with antifibrotics, al-
though no significant differences were seen: FVC 460.0
(215.0–732.5) mL or 13.0 (4.8–18.0) %pred (p = 0.69);
TLC 945.0 mL (362.5–1490) or 10.0%pred (2.0–20.0)
(p = 1.0); and DLCO 1.26 (0.38–2.09) mmol/min/Kpa or
14.0 (4.0–24.8) %pred (p = 0.94).
6MWT was performed before the start of antifibrotic
therapy and consecutive 6MWT was available in 5/9
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patients (all on pirfenidone), of whom 3/5 were enrolled
in a pretransplant cardio-pulmonary rehabilitation (CPR)
program upon transplant listing and 2/5 were not.
6MWT overall increased with 54 (−260.0–95.5) m after
12 weeks of treatment compared to baseline (p = 0.62),
with an improved in 4/5 patients of 74.5 (21.8–95.8) m,
while one patient demonstrated a decline of 531 m (pa-
tient n°5 in Table 1, no CPR, concomitant decline in
FVC of 12%pred during these 12 weeks of treatment).
During the whole pretransplant time period of antifibro-
tic treatment (59 ± 44 weeks), 6MWT did not signifi-
cantly change compared to baseline (p = 0.89): 6MWT
improved compared to baseline in 2/5 patients (+63 m
(no CPR) and +142 m (with CPR), respectively), while
6MWT deteriorated in 3/5 patients (one no CPR, two
with CPR), in whom there was an absolute decline of
−172 (34–531) meters or a monthly decline of −5.2
(2.7–85.7) meters during treatment (Fig. 2). In the
historical controls, unfortunately, 6MWD was only
available upon listing for LTx, thus no consecutive
6MWT were available for further comparison.
Transthoracic echocardiography performed before
start of antifibrotic therapy (pulmonary arterial pres-
sure (PAP) 31.1 ± 7.4 mmHg) and consecutive echocar-
diography was available in 4/9 patients, in whom PAP
tended to increase during antifibrotic treatment (PAP
+9.5 (2.0–15.5) mmHg: p = 0.090). Renal function
remained stable during antifibrotic treatment: serum
creatinine was 0.96 ± 0.14 mg/dL at start versus 0.95 ±
0.17 mg/dL at LTx (p = 0.97), estimated glomerular fil-
tration rate was 83 ± 13 mL/min/1.73 m2 at start versus
82 ± 14 mL/min/1.73 m2 at LTx (p = 0.83). No hepatic
dysfunction was observed in any patient during treat-
ment. LAS did not significantly change during antifi-
brotic treatment: 32.2 ± 2.5 at start of therapy versus
32.3 ± 1.0 at LTx (p = 0.13).
Post-transplant outcomes
Patients receiving antifibrotics were listed for 155
(40–299) days before subsequent LTx. Transplant pro-
cedures were overall uneventful and only one patient
(who had received pirfenidone, had the highest pretrans-
plant PAP of 48 mmHg and underwent single sided LTx)
required peri-operative support with veno-arterial extra-
corporeal membrane oxygenation. There were no bleeding
problems (i.e. no need for re-thoracotomy for hemotho-
rax, no additional transfusion of blood products for blood
loss) in any patient, including those on nintedanib. Over-
all, patients were extubated after 37.0 (33.5–53.0) hours of
ventilation, discharged from the intensive care unit after
6.4 ± 3.2 days and discharged home after a hospital stay of
20.3 ± 4.6 days. There were no problems with post-
operative thoracic wound healing or dehiscence in any pa-
tient. All patients, but one, received post-operative induc-
tion therapy with anti-thymocyte globulin for 3 days; and
post-operative immunosuppressive regimen consisted of
tacrolimus, mycophenolate mofetil and steroids in all pa-
tients, except one (transplanted in 2008) who received
cyclosporine, azathioprine and steroids (our standard regi-
men before 2010). No major side effects due to possible
drug-interactions with prior antifibrotics were seen in the
first days post-LTx.
A total of 4/9 patients were included in a clinical trial
immediately following LTx: 2 in a therapeutic trial with
azithromycin (AZI003, NCT01915082), 1 in an ex-vivo
normothermic machine perfusion trial (EXPANDLung,
NCT01963780) and 1 in a Diaphragm Pacing trial
(NCT02411383), which may obviously influence early
and/or late outcomes (including post-transplant evolu-
tion of pulmonary function, anastomotic airway compli-
cations, primary graft dysfunction (PGD), rejection,
infection, CLAD) in these transplant recipients com-
pared to those not included in a trial or historical
controls. Overall, incidence of PGD (PGD ≥ 2 in 5/9
patients), early post-operative infection (5/9 patients)
and acute cellular rejection (4/9 patients) or lympho-
cytic bronchiolitis (4/9) during the first 6 months
were comparable to findings in the historical controls
(all p > 0.5) (Table 1).
Anastomotic airway complications were present in 4/9
patients: in two patients (prior pirfenidone) mild anasto-
motic necrosis without dehiscence or airway narrowing
was noted upon discharge after LTx (post-operative day
Fig. 1 Forced Vital Capacity in IPF patients with at least 6 months
antifibrotic therapy before transplantation. Forced Vital Capacity
(FVC) (%predicted) is given at the start of antifibrotic therapy (start),
3 months before and respectively 3, 6, 9 and 12 months (mo) after
start. Dotted lines connect values in patients (n = 6/9) with consecutive
measurements at different time points; p-values (Wilcoxon signed rank
test) above each time point are given compared to start; or compared
another time point (time-frame indicated by full line)
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(POD) 30; MDS classification M2aD0aS0 for right-sided
anastomosis and M0aD0aS0 for left-sided anastomosis in
both patients), with spontaneous and uncomplicated reso-
lution thereafter. In a third patient (initially no anastomotic
complications, prior nintedanib), there was mild protrusion
of cartilage on POD 90 (M0aD0aS0 for right-sided anasto-
mosis and M1aD0aS0 for left-sided anastomosis), with
spontaneous and uncomplicated resolution thereafter. In
the fourth patient (initially no anastomotic complications,
prior pirfenidone), following infection with Aspergillus
fumigatus at POD 186, late-onset (POD 204) anastomotic
necrosis occurred with bronchial narrowing and extensive
dehiscence (M0aD0aS0 for right-sided anastomosis and
M3bD2cS2f for left-sided anastomosis). Despite antifungal
treatment, he developed severe symptomatic anastomotic
stenosis, which finally required surgical sleeve-resection
and reconstruction of the left main bronchus on POD
410. Thereafter, no other problems occurred and the
patient currently has a stable pulmonary function at
POD 525. The observed anastomotic airway complica-
tions, however, did not appear to be more severe or
prevalent compared to previously reported data from
our centre [11] or to the historical controls, of whom
4/6 controls had early anastomotic airway complica-
tions (ranging from M2aD0aS0 to M3bD2bS0; Table 1).
Overall, long-term outcome in our cohort was good:
after a median follow-up of 19.8 (11.2–26.5) months,
currently all patients have a stable pulmonary function
(Table 1) and none of the patients has developed CLAD.
One patient (who underwent single sided LTx), unfortu-
nately, has died because of non-squamous large cell lung
carcinoma of his native IPF lung on POD 615, all other
patients are alive and ambulatory at present. Overall
survival was 100% after 1 year and 80% after 2 years,
respectively.
Discussion
Little is known about safety of antifibrotic therapy with
pirfenidone or nintedanib in patients undergoing LTx.
Actually only 11 IPF patients receiving pirfenidone; and
none receiving nintedanib, included in the large ran-
domized trials with these drugs (comprising a total of
2832 study-subjects) were reported as having been
transplanted during antifibrotic treatment, yet detailed
outcome data for these patients are lacking [3–7]. Only
1 case report has currently been published on
Fig. 2 Pretransplant evolution of pulmonary function and functional exercise capacity following treatment with antifibrotic drugs. Forced Vital Capacity
(FVC) (a), Total Lung Capacity (TLC) (b), Diffusion capacity (DLCO) (c) (all in (%predicted) and 6 min walk test (6MWT, meter) (d) at start of antifibrotic therapy
(start) and at the moment of lung transplantation (LTx) in the included IPF patients. Dotted lines connect values in patients (n= 6/9) with a consecutive
measurement at six months and just before transplantation; p-values (Wilcoxon signed rank test) are given for patients that had consecutive measurements
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pretransplant pharmacological bridging with pirfeni-
done, allowing stabilization of respiratory function and
subsequent single sided LTx in IPF. Anastomic airway
complications, however, were not reported in this case
[12]. Next to this, there have been two abstracts report-
ing on this topic, which did not yet result in peer-
reviewed papers, but in which, apparently, pirfenidone
therapy was not linked to adverse post-transplant
events, however follow-up was limited and detailed
outcome data missing [13, 14]. In the current case
series, we therefore report on pre-operative evolution
and post-transplant outcomes of 9 IPF patients, treated
with either pirfenidone or nintedanib for a mean of
13.4 months until subsequent LTx and with a median
post-transplant follow-up of 19.8 months.
According to the same definitions used in larger IPF
trials [6, 15], we noted relative stabilization (i.e. < 10%
change) of FVC during the first 12 weeks of antifibrotic
treatment. Importantly, this early stabilization, or per-
haps better attenuated rate of decline, in FVC may by no
means be a reason to deny subsequent LTx to eligible
patients, because further decline in FVC, lung volumina
and DLCO is to be expected despite antifibrotic treat-
ment, as was obvious from our results. The estimated
annual decline in FVC during treatment in our cohort,
however, would be around 6.6%pred, which corroborates
recent findings that both pirfenidone and nintedanib re-
duce the proportion of patients with a ≥10% decline in
FVC %pred after 1 year of treatment [5, 6]. As they may
attenuate disease progression, these antifibrotics may
thus allow for valuable added time on the LTx waiting
list. Next to FVC, 6MWT has also been shown to be a
valid outcome measure, both in IPF, in whom the clinic-
ally important difference in 6MWT distance is reported
to be 24–45 m [3–5] and in whom 6MWT is associated
with changes in pulmonary function and quality-of-life
[16]; and in patients awaiting LTx, in whom it is associ-
ated with post-transplant survival [17]. A reduction of
the decline in 6MWT was also observed in treated pa-
tients compared to placebo in pooled analyses of IPF tri-
als [3–5], which may partly explain why 6MWT overall
remained relatively stable during treatment in our co-
hort, next to the obvious beneficial effects of cardio-
pulmonary rehabilitation is some patients. Although the
LAS is actually not used in Belgium for prioritizing
organ allocation, the calculated LAS (which includes
FVC and 6MWT among other parameters) did not sig-
nificantly change during pretransplant antifibrotic treat-
ment in our cohort. An average LAS of 32 at the time of
LTx in our study may seem fairly low for IPF patients,
yet LAS was quite comparable between our treated
patients and historical controls; and was in the same
range (median of ±35) as previously described for IPF
patients at LTx listing [18]. We therefore believe that
our cohort indeed reflects the general population of IPF
patients transplanted during the past 5–10 years. How-
ever, in the last few years, as seen in the US, an increase
in LAS is also noted in our centre, with more sicker pa-
tients (LAS > 40) being listed for LTx [19].
No serious side effects were noted during antifibrotic
therapy. However, significant weight loss occurred, which
is most likely due to drug-induced anorexia or possibly
due to respiratory cachexia in end-stage lung disease.
Post-operatively, no problems with bleeding or thoracic
wound healing were observed. One patient, treated with
nintedanib; and three patients who had received pirfeni-
done developed, mostly mild and uneventful, anastomic
airway complications. Intervention for anastomotic sten-
osis was needed for one case, which only occurred late-
onset after prior fungal infection. Overall, it is unlikely that
any of these anastomotic problems were directly related to
prior antifibrotic treatment given the time of onset/clinical
context of anastomotic complications, comparable anasto-
motic problems in the historical controls; and rather short
half-life of both drugs (for pirfenidone 3 h, for nintedanib
9.5 h) [20, 21]. The short half-life of both antifibrotic
drugs is important, as drug-interactions with calcine-
urin inhibitors, by altered hepatic (CYP3A4) metaboli-
sation leading to changes in tacrolimus/cyclosporine
trough levels, are a feared iatrogenic adverse event in LTx.
However, hepatic metabolism of pirfenidone primarily oc-
curs through the CYP1A2 enzyme; whereas nintedanib is
mainly a substrate of P-glycoprotein (P-gp) and only
weakly interferes with CYP3A4. This probably also ex-
plains why no major side effects due to drug-interactions
with peri-operatively used drugs were noted in our cohort.
Finally, long-term outcomes regarding pulmonary func-
tion and overall survival were overall good in our current
case series, suggesting that antifibrotic agents can prob-
ably be safely given without deleterious effects on peri-
operative or medium-term outcomes.
Possible limitations of the current study, of course, are its
retrospective design, the small number of included patients;
and historical controls as comparator for some outcomes,
which of course limits interpretations regarding antifibrotic
drug efficacy and safety. Also, disease severity ranged from
mild to severe IPF, which may bias the observed effects of
pretransplant antifibrotic therapy; and post-transplant evo-
lution, including pulmonary function, may be biased by in-
clusion of some patients in various randomized clinical
trials. Larger, preferably prospective, case-series are there-
fore undeniably needed to confirm our findings, especially
for nintedanib additional safety data are needed before fir-
mer conclusions can be made regarding its safety.
Conclusion
In summary, we conclude that antifibrotic drugs are prob-
ably safe in IPF patients undergoing LTx. By attenuating
Delanote et al. BMC Pulmonary Medicine  (2016) 16:156 Page 9 of 10
disease progression while awaiting LTx, these antifibrotics
may perhaps further help to reduce the number of IPF pa-
tients dying on the waiting list.
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